newsfilter
← Latest News
Business Wire·

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

  • Natera's Signatera molecular residual disease (MRD) test was named to TIME's Best Inventions of 2026 list in the Medical & Healthcare category.
  • Natera was also included in Fortune's Future 120 list in October 2026 to highlight its role in defining future business & innovation.
  • Signatera detects & quantifies circulating tumor DNA (ctDNA) to monitor disease recurrence & treatment response across various cancer types.
  • The test is the most widely adopted MRD test, supported by over 200 peer-reviewed publications & used by more than 55% of U.S. oncologists.
  • CEO Steve Chapman stated Signatera can detect disease recurrence up to two years prior to imaging to guide therapy decisions.
  • The test supports oncology drug development by helping pharmaceutical companies identify patients for clinical trials & accelerate therapy approvals.
  • Natera operates ISO 13485-certified & CAP-accredited laboratories in Texas, California, & Colorado, supported by over 400 peer-reviewed publications.